Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia Court Rules For Pfizer In Ranbaxy Lipitor Patent Suit

This article was originally published in PharmAsia News

Executive Summary

Australia's federal court ruled in favor of Pfizer in a case that had challenged its patent for atorvastatin, Lipitor's active ingredient. The same court, however, declared invalid Pfizer's patent for the calcium salt that is part of atorvastatin. Ranbaxy Laboratories, which sought to make a generic version of the drug, had challenged the patent, which now is valid through 2012. Pfizer says it could appeal the court's ruling on the calcium salt patent. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts